GDRXGoodRx Holdings Inc

Quick Summary

GoodRx Holdings, Inc. is a U.S. healthcare technology and consumer savings company that helps people compare prescription drug prices and access negotiated discounts. Its core business is a prescription price comparison platform that shows geographically relevant prices at pharmacies and helps consumers save on out-of-pocket medication costs. The company also offers subscription programs, pharmaceutical manufacturer solutions, telehealth-related services, and newer direct-to-consumer drug access initiatives. Its main customers include consumers paying cash for prescriptions, underinsured patients, people with high deductibles, employers seeking lower-cost medication access for workers, pharmaceutical manufacturers, and pharmacy partners. GoodRx operates in the business services and healthcare technology ecosystem, with revenue tied to prescription transaction activity, advertising or manufacturer programs, subscriptions, and partnerships.

Key Risks

• GoodRx faces significant risk from changes in PBM economics, pharmacy reimbursement pressure, and pharmacy partner behavior.
• If pharmacies reduce participation, close locations, or negotiate less favorable terms, GoodRx’s consumer value proposition and transaction revenue could decline.
• Amazon’s growing presence in online pharmacy and GLP-1 sales is a major competitive risk because Amazon has scale, fulfillment strength, and a massive Prime user base.
• Regulatory changes, drug pricing reforms, or scrutiny of discount card economics could also affect the company’s business model.

What to Watch

Price Drivers

• GoodRx’s stock price is being driven by the tension between weak or pressured legacy discount-card growth and potential upside from new pharma, employer, and direct-to-consumer programs.
• The company reported recent quarterly revenue around $194 million, modest profitability, and a high price-to-earnings multiple, which makes investor sentiment sensitive to growth assumptions.
• News that GoodRx would sell Novo Nordisk’s FDA-approved GLP-1 drugs Ozempic and Wegovy for $499 per month cash caused a sharp stock reaction because investors saw a possible new growth category.
• Analyst fair value estimates cited in recent news range around $4.56 to $5.09, but those estimates were influenced by higher risk assumptions, lower growth forecasts, and uncertainty about future margins.

Recent News

• Recent news reports said GoodRx’s fair value estimate was kept around $5.09 by one analysis despite higher risk assumptions and lower growth or margin expectations.
• Other analysts trimmed an estimate to about $4.56 from $4.95, citing higher risk and lower assumptions, while still describing potential upside if new partnerships work.
• GoodRx announced that it would sell Novo Nordisk’s FDA-approved GLP-1 drugs Ozempic and Wegovy for $499 per month cash, and the stock reportedly rose more than 30% on that news.
• The company also reported Q4 2025 revenue of about $194.8 million and full-year revenue of about $796.9 million, with 2026 guidance of $750 million to $780 million.

Market Trends

• The healthcare market is shifting toward more direct-to-consumer drug distribution, online pharmacy access, and cash-pay models for certain high-demand medications.
• GLP-1 drugs for diabetes and weight loss are one of the most important current trends, with Novo Nordisk, Eli Lilly, Amazon, Hims & Hers, WeightWatchers, and other players competing for patient access and pricing models.
• Employers are increasingly concerned about the cost of obesity and diabetes drugs, which creates opportunities for platforms that can help manage subsidies and negotiated access.
• At the same time, PBMs, pharmacies, and drug manufacturers are reworking distribution and reimbursement models, which can create both upside and disruption for intermediaries like GoodRx.